Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 973 of 6351
-
8,000 stroke survivors join hunt to predict dementia risk
Knowledge-focused Recruiting nowThe overall goal of the DISCOVERY study is to better understand what factors contribute to changes in cognitive (i.e., thinking and memory) abilities in patients who experienced a stroke. The purpose of the study is to help doctors identify patients at risk for dementia (decline …
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Cheap pill could save millions from blindness, major trial launches
Prevention OngoingThis randomized trial will evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening through 6 years of follow-up in eyes with mild to moderately severe non-proliferative DR (NPDR) and no CI-DME at baseline. In addition to eva…
Phase 3 • Sponsor: Jaeb Center for Health Research • Aim: Prevention
Last updated Jul 01, 2026 00:00 UTC
-
New hope for hard-to-treat colon cancer: targeted drug shrinks tumors
Disease control CompletedThis study will evaluate the efficacy, safety, and pharmacokinetics of Trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor 2 (HER2)-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC).
Phase 2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Hydrogel could starve tumors by cutting off their blood supply
Disease control CompletedTo determine whether Instylla HES has the ability to effectively embolize targeted arterial segments of hypervascular tumors as well as (i.e., is non-inferior to) standard of care (SOC) transarterial embolization/conventional transarterial chemoembolization, while resulting in an…
Sponsor: Instylla, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Immune cells engineered to hunt brain tumors in spinal fluid show promise in early trial
Disease control OngoingThis phase I trial investigates the side effects of brain tumor-specific immune cells (IL13Ralpha2-CAR T cells) in treating patients with leptomeningeal disease from glioblastoma, ependymoma, or medulloblastoma. Immune cells are part of the immune system and help the body fight i…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for vision loss: Long-Term study of pegcetacoplan for dry AMD
Disease control CompletedThis is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who participated in Study APL2-103 (NCT03777332) or comp…
Phase 3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Weight-Loss drug for kids? new trial tests liraglutide in children as young as 6
Disease control OngoingThe study looks at how liraglutide works on participant's body weight. Researchers will look at how liraglutide can help children with obesity to lose weight. They will look at how much weight the children will lose, and if there are any side effects. Participants will either ge…
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New hope for GVHD patients who failed other treatments
Disease control Recruiting nowThis is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received at least 2 prior lines of systemic therapy.
Phase 2 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Lupus drug sirolimus shows promise in phase 3 trial
Disease control OngoingThis is a multi-center, double-blinded, randomized, placebo-controlled, phase 3 study to evaluate the efficacy and safety of sirolimus administered in addition to standard therapy, in patients with active SLE disease.
Phase 3 • Sponsor: Chinese SLE Treatment And Research Group • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug cocktail shows promise against tough head and neck cancer
Disease control CompletedThe primary objective of this study is to evaluate the efficacy of atezolizumab plus tiragolumab and atezolizumab plus placebo as first-line (1L) treatment in recurrent/metastatic PD-L1-positive squamous cell carcinoma of the head and neck (SCCHN) on the basis of confirmed object…
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
A Pocket-Sized coach for sickle cell: can an app turn Pill-Taking into a habit?
Disease control CompletedThe primary objective of this study is to better understand factors contributing to variations in hydroxyurea (HU) adherence behavior in adolescents and young adults (AYA) with sickle cell disease (SCD). To meet this objective, the researchers will conduct a prospective cohort st…
Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Blood test may predict kidney decline in diabetes — a large trial investigates
Diagnosis Recruiting nowThe purpose of this study is to assess the impact of the KidneyIntelX assay utilized as part of the current standard of care on the management of patients seen in the primary care physician's office at Mount Sinai.
Sponsor: Renalytix AI, Inc. • Aim: Diagnosis
Last updated Aug 15, 2026 00:00 UTC
-
Should High-Risk CLL patients start treatment early? major trial aims to find out
Disease control Recruiting nowThis phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications …
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New cocktail aims to boost remission in rare blood cancer
Disease control OngoingThis is a multi-centre, open label, single-arm, phase II clinical trial in untreated patients with Waldenstrom's Macroglobulinemia. Symptomatic, previously untreated patients will receive SOC bendamustine and rituximab for 6 28-day cycles. Bendamustine will be given intravenously…
Phase 2 • Sponsor: Sunnybrook Health Sciences Centre • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Poop pills could stop deadly transplant complication
Disease control Recruiting nowTo evaluation the efficacy and safety of autologous fecal bacteria transplantation in preventing acute graft versus host disease after haploidentical hematopoietic stem cell transplantation. Bone marrow transplant patients were recruited.
Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug cocktail shows promise against tough breast cancer
Disease control OngoingThis phase I/II trial studies the side effects and best dose of copanlisib and how well it works when given together with eribulin in treating patients with triple negative breast cancer that has spread from where it first started (primary site) to other places in the body (metas…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug combo aims to block prostate cancer return in High-Risk men
Disease control OngoingThis phase III trial compares the effect of adding darolutamide to ADT versus ADT alone after surgery for the treatment of high-risk prostate cancer. ADT reduces testosterone levels in the blood. Testosterone is a hormone made mainly in the testes and is needed to develop and mai…
Phase 3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Massive stroke drug study shows Real-World results
Disease control CompletedThe aim of FORPI Registry is to study the safety and efficacy of the non-immunogenic staphylokinase in patients with acute ischemic stroke in routine clinical practice.
Sponsor: Supergene, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New hope for advanced stomach cancer: drug combo targets patients who failed first-line therapy
Disease control Recruiting nowThis study was an open, single center, prospective cohort study design. Subjects with advanced gastric cancer who had received first-line chemotherapy (cohort 1) and systematic chemotherapy combined with immunotherapy (cohort 2) were included in this study. 20 cases were included…
Phase 2 • Sponsor: Shandong Tumor Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Can a gene test spare breast cancer patients from extra radiation?
Disease control Recruiting nowThe effect of internal mammary irradiation (IMI) added to whole-breast or thoracic-wall irradiation plus supraclavicular (SVC) irradiation after surgery on survival among women with early-stage intermediate risk (N1) breast cancer remains debated. The present study aimed to ident…
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC